PETVIVO HOLDINGS, INC. ANNOUNCES DISTRIBUTION OF ITS VETERINARY MEDICAL DEVICE, SPRYNG™, BY VETCOVE, INC.
January 05 2022 - 7:30AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets is pleased to announce
that VetCove, Inc. has agreed to distribute PetVivo’s therapeutic
product, SPRYNG™ with OsteoCushion™ Technology. VetCove owns and
operates a licensed veterinarian ordering/purchasing platform used
by over 13,000 veterinary hospitals to compare prices and purchase
medications, food and veterinary supplies from multiple vendors at
once.
“We are excited to announce that VetCove has
approved for distribution our proprietary veterinary medical
device, Spryng with OsteoCushion Technology, through its licensed
veterinarian ordering/purchasing platform” said John Lai, Chief
Executive Officer of PetVivo. “VetCove’s licensed veterinarian
ordering platform introduces Spryng to more than 13,000 veterinary
hospitals and provides veterinarians the opportunity to order and
administer SPRYNG to dogs and horses suffering from osteoarthritis
and other lameness afflictions.”
PetVivo’s innovative therapeutic product,
Spryng™ with OsteoCushion™ Technology, is a veterinary medical
device comprised of millions of micronized hydrogel matrices, which
are derived from natural components, collagen and elastin.
OsteoCushion Technology provides both reinforcing natural joint
support to replace and/or reinforce missing and damaged cartilage,
as well as delivers natural scaffolding to help address tissue
defects. These attributes offer a great solution to manage lameness
and joint afflictions, such as osteoarthritis, for companion
animals in a simple in-clinic treatment.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is scheduled for
expanded commercial sale in the fourth quarter of this year.
CONTACT:
John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Mar 2024 to Apr 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Apr 2023 to Apr 2024